We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Rapid POC Test for Diagnosis of Preeclampsia Could Prevent Unnecessary Hospitalization

By LabMedica International staff writers
Posted on 16 May 2022

Preeclampsia is a pregnancy disorder that can have devastating effects on the health of the mother and the unborn baby. More...

Affecting 5-8% of all pregnancies, it is a rapidly progressive and potentially deadly condition. A correct diagnosis of the pregnancy disorder is currently time-consuming and, in many cases, inaccurate. Now, a fast and precise point-of-care test for preeclampsia is being developed that would provide diagnostic certainty and at the same time, save healthcare costs.

MOMM Diagnostics (Basel, Switzerland) is developing a rapid test for preeclampsia that would offer unprecedented sensitivity at the point-of-care. MOMM develops high-sensitivity rapid diagnostic tests. Immediate information during pregnancy check-ups will help doctors to optimize treatment, reduce stress and anxiety for expectant mothers, save lives and reduce costs. The rapid test for preeclampsia will be based on the company’s technology that combines the commercial advantage of lateral flow immunoassays, with the sensitivity of ELISA, and reader simplicity similar to blood glucose meters.

Since pregnant women regularly go to medical check-ups, the test can be carried out at the gynecologist without the need to send blood samples to a specialized diagnostics lab. The rapid screening test for preeclampsia will also spare expectant mothers the long wait for lab results. This will save valuable time and enable treatment to be started quickly. By providing diagnostic certainty, the test would also eliminate the possibility of false positive results by conventional tests that can create unnecessary anxiety for pregnant women.

Related Links:
MOMM Diagnostics 


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: Powered by OptraSCAN’s patented OS‑SiA technology, the platform performs scanning, indexing, and AI‑driven analysis simultaneously (Photo courtesy of OptraSCAN)

New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow

Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. Yet consistent, repeatable bacillary assessment... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.